Becton Dickinson and Co (NYSE:BDX) EVP Patrick Kaltenbach sold 191 shares of the firm’s stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $241.03, for a total value of $46,036.73. Following the transaction, the executive vice president now directly owns 19,072 shares of the company’s stock, valued at approximately $4,596,924.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Patrick Kaltenbach also recently made the following trade(s):
- On Tuesday, June 4th, Patrick Kaltenbach sold 275 shares of Becton Dickinson and stock. The shares were sold at an average price of $235.00, for a total value of $64,625.00.
BDX traded up $0.03 during trading on Wednesday, hitting $237.05. 21,316 shares of the company’s stock traded hands, compared to its average volume of 1,273,610. The company has a market cap of $63.73 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 1.76 and a beta of 1.11. Becton Dickinson and Co has a 12-month low of $208.62 and a 12-month high of $265.87. The company has a current ratio of 0.96, a quick ratio of 0.59 and a debt-to-equity ratio of 0.82.
Becton Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, May 9th. The medical instruments supplier reported $2.59 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.57 by $0.02. The firm had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a return on equity of 14.58% and a net margin of 5.88%. The company’s revenue for the quarter was down .6% on a year-over-year basis. During the same period last year, the business posted $2.65 EPS. As a group, research analysts forecast that Becton Dickinson and Co will post 11.69 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Friday, June 7th will be paid a $0.77 dividend. The ex-dividend date is Thursday, June 6th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 1.30%. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.97%.
A number of research firms recently weighed in on BDX. Wells Fargo & Co reduced their price objective on Becton Dickinson and from $280.00 to $265.00 and set an “outperform” rating for the company in a research report on Monday, May 13th. UBS Group cut their target price on Becton Dickinson and from $265.00 to $250.00 and set a “neutral” rating on the stock in a research note on Friday, May 10th. BMO Capital Markets cut their target price on Becton Dickinson and from $272.00 to $270.00 and set a “market perform” rating on the stock in a research note on Friday, May 10th. ValuEngine downgraded Becton Dickinson and from a “buy” rating to a “hold” rating in a research note on Monday, April 1st. Finally, Zacks Investment Research upgraded Becton Dickinson and from a “sell” rating to a “hold” rating in a research note on Tuesday, April 30th. Six investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $255.31.
Several hedge funds have recently added to or reduced their stakes in BDX. Harvest Group Wealth Management LLC purchased a new position in Becton Dickinson and during the first quarter valued at $25,000. Oregon Public Employees Retirement Fund lifted its position in Becton Dickinson and by 22,485.4% during the fourth quarter. Oregon Public Employees Retirement Fund now owns 6,574,612 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 6,545,502 shares in the last quarter. Pinnacle Financial Partners Inc. purchased a new position in Becton Dickinson and during the first quarter valued at $29,000. RPG Investment Advisory LLC purchased a new position in Becton Dickinson and during the first quarter valued at $32,000. Finally, Nalls Sherbakoff Group LLC purchased a new position in Becton Dickinson and during the fourth quarter valued at $34,000. Hedge funds and other institutional investors own 84.58% of the company’s stock.
WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2019/06/12/becton-dickinson-and-co-nysebdx-evp-sells-46036-73-in-stock.html.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.
Recommended Story: Quiet Period Expirations
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.